<DOC>
	<DOCNO>NCT00000668</DOCNO>
	<brief_summary>To determine pharmacokinetics ( blood level ) three dose treatment plan oral ganciclovir 28-day dosing period . Other purpose study determine population HIV seropositive person cytomegalovirus ( CMV ) viremia , safety , tolerance , patient acceptability oral ganciclovir give 28 day , collect preliminary laboratory evidence antiviral activity effectiveness three dose regimens oral ganciclovir base blood urine culture CMV , relate antiviral activity dosage serum ganciclovir level . CMV retinitis important sight-threatening opportunistic infection affect 10 15 percent people AIDS . A previous study show treatment ganciclovir result significant delay time first retinitis progression compare untreated control . More study warrant evaluate effect different dos .</brief_summary>
	<brief_title>A Phase I Pharmacokinetic Tolerance Study 28-Day Regimens Oral Ganciclovir</brief_title>
	<detailed_description>CMV retinitis important sight-threatening opportunistic infection affect 10 15 percent people AIDS . A previous study show treatment ganciclovir result significant delay time first retinitis progression compare untreated control . More study warrant evaluate effect different dos . In group A , 36 HIV seropositive patient CMV viruria receive single dose intravenous ganciclovir follow one three oral dose regimens 28 day . Twelve individual treat dose level . In group B , 12 patient AIDS CMV retinitis receive oral ganciclovir therapy . These 12 patient must receive induction course intravenous ganciclovir 4 week prior study entry must stable CMV retinitis . Measurements group include pharmacokinetics , safety , tolerance ( history , physical examination , hematology , serum chemistry ) , CMV blood urine culture . In addition , weekly ophthalmologic evaluation individual group B study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Topical acyclovir . There two group patient . Group A must : Confirmation HIV infection HIV antibody test , p24 antigen , culture HIV . A positive urine culture cytomegalovirus ( CMV ) within 4 week study entry . Not receive prior ganciclovir therapy . Group B must : A diagnosis AIDS CDC criterion . CMV retinitis diagnose funduscopic evaluation ophthalmologist . Completed 4 week intravenous ganciclovir improvement stabilization retinitis . The course therapy include minimum 24 day total intravenous ganciclovir . Patients group must understand nature study , agree test require protocol , must understand sign inform consent form approve appropriate Institutional Review Board ( IRB ) Syntex . Required : Group B : 4 week intravenous ganciclovir include minimum 24 day total intravenous ganciclovir . Exclusion Criteria Coexisting Condition : Patients follow exclude : Macular involvement due cytomegalovirus ( CMV ) retinitis eye . Active CMV retinitis progression . Presence diarrhea clinically significant uncontrolled gastrointestinal disease include persistent nausea and/or abdominal pain . Diarrhea define &gt; 3 unformed stools/day . Dementia decrease mentation encephalopathic sign symptom would interfere ability patient follow protocol , take assign dose regimen reliably , keep daily record calendar . Significant CMV disease organ , include CMV gastroenteritis CMV pneumonia . Concurrent Medication : Excluded : Any investigational drug . Acyclovir specifically allow . Any nucleoside analog . Zidovudine ( AZT ) . Probenecid . Aspirin . Patients follow exclude : Macular involvement due cytomegalovirus ( CMV ) retinitis eye . Active CMV retinitis progression . CMV end organ disease . Presence diarrhea clinically significant uncontrolled gastrointestinal disease include persistent nausea and/or abdominal pain . Diarrhea define &gt; 3 unformed stools/day . Dementia decrease mentation encephalopathic sign symptom would interfere ability patient follow protocol , take assign dose regimen reliably , keep daily record calendar . Significant CMV disease organ , include CMV gastroenteritis CMV pneumonia . Prior Medication : Excluded within 4 day study entry : Antimetabolite . Interferon . Other nucleoside analog include zidovudine ( AZT ) . Excluded Group A : Ganciclovir anticytomegalovirus therapy .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>